Clinical Trials Browser

Multiple Myeloma × selinexor × 1 year × Clear all

NCT06169215 2026-04-13

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma

NCT07200102 2026-03-23

Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma

NCT07479979 2026-03-23

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT06158841 2026-03-13

CERVINO

Phase 3 Recruiting

Multiple Myeloma

NCT07215832 2026-03-02

KEAP

GynecologicLymphoidMyeloidPlasma cellSarcoma

Multiple Myeloma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Endometrial Neoplasms, Primary Myelofibrosis

NCT03589222 2026-02-27

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma

NCT07138209 2026-02-27

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT04764942 2026-02-25

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT05530421 2026-02-23

SELVEDge

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT04661137 2026-02-10

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

Phase 2 Suspended

Multiple Myeloma

NCT04414475 2026-02-02

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Phase 2 Recruiting

Multiple Myeloma

NCT05954780 2026-01-14

SEATTLE

Active not recruiting

Multiple Myeloma

NCT04640779 2026-01-06

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma

Phase 1 Active not recruiting

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT05675319 2026-01-05

AlloRelapseMM

Phase 3 Terminated

Multiple Myeloma

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT05028348 2025-12-04

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Phase 3 Active not recruiting

Multiple Myeloma

NCT02199665 2025-11-03

SINE

Phase 1 Completed

Multiple Myeloma

NCT06822972 2025-09-02

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

Phase 2 Recruiting

Multiple Myeloma

NCT05900882 2025-08-17

SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

Phase 2 Recruiting

Multiple Myeloma